For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
26
views
24
references
 Top references
cited by
243
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      2,959
      similar
       All similar
      • Record: found
      • Abstract: not found
      • Article: not found

      Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma : The ESCORT-1st Randomized Clinical Trial

      Author(s): 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 28 , 28 , 1 , 2 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , 29 , ESCORT-1st Investigators
      Publication date Created:
      Publication date (Print):
      Journal: JAMA
      Publisher: American Medical Association (AMA)

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: found
          • Article: not found

          Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

          Rina Hui, Takayasu Kurata, Silvia Novello … (2018)
          First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the first-line treatment of choice. The addition of pembrolizumab to chemotherapy resulted in significantly higher rates of response and longer progression-free survival than chemotherapy alone in a phase 2 trial.
          Article 0 comments Cited 2128 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

            Barbara Burtness, Kevin Harrington, Richard Greil … (2019)
            Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response.
            Article 0 comments Cited 992 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Proportional hazards tests and diagnostics based on weighted residuals

              PATRICIA GRAMBSCH, Terry Therneau (1994)
              Article 0 comments Cited 552 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Title: JAMA
                Abbreviated Title: JAMA
                Publisher: American Medical Association (AMA)
                ISSN (Print): 0098-7484
                Publication date Created: September 14 2021
                Publication date (Print): September 14 2021
                Volume: 326
                Issue: 10
                Page: 916
                Affiliations
                [1 ]Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
                [2 ]Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China
                [3 ]Sichuan Cancer Hospital, Chengdu, China
                [4 ]Harbin Medical University Cancer Hospital, Harbin, China
                [5 ]Shanghai Chest Hospital, Shanghai, China
                [6 ]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
                [7 ]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
                [8 ]Zhejiang Cancer Hospital, Hangzhou, China
                [9 ]Fudan University Shanghai Cancer Center, Shanghai, China
                [10 ]The Second Affiliated Hospital of Anhui Medical University, Hefei, China
                [11 ]The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, China
                [12 ]Fujian Provincial Cancer Hospital, Fuzhou, China
                [13 ]900 Hospital of the Joint Logistics Support Force, Fuzhou, China
                [14 ]The First Affiliated Hospital of Anhui Medical University, Hefei, China
                [15 ]Jiangxi Provincial Cancer Hospital, Nanchang, China
                [16 ]Hunan Cancer Hospital, Changsha, China
                [17 ]Peking University Cancer Hospital and Institute, Beijing, China
                [18 ]Jiangsu Cancer Hospital, Nanjing, China
                [19 ]Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China
                [20 ]Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
                [21 ]The Second Affiliated Hospital of Air Force Medical University, Xi'an, China
                [22 ]Henan Cancer Hospital, Zhengzhou, China
                [23 ]Chongqing Three Gorges Central Hospital, Chongqing, China
                [24 ]Anhui Chest Hospital, Hefei, China
                [25 ]Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
                [26 ]Jilin Cancer Hospital, Changchun, China
                [27 ]Army Medical Center of PLA, Chongqing, China
                [28 ]Jiangsu Hengrui Pharmaceuticals Co, Ltd, Shanghai, China
                [29 ]for the ESCORT-1st Investigators
                Article
                DOI: 10.1001/jama.2021.12836
                PubMed ID: 34519801
                SO-VID: 75002564-9160-4189-80d9-1f8eb4ae178d
                Copyright © © 2021
                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content2,959

                See all similar

                Cited by243

                See all cited by

                Most referenced authors1,024

                See all reference authors